HAX’s VC-Founder Industry Hard Tech Matchup is now accepting applications. Register today!


PONS creates disease progression insights that were never collected before.


Soner Hacihaliloglu


Ilker Hacihaliloglu


Company details

PONS is disrupting the $100B clinical trial and biomarker industry by converting any mobile ultrasound into a powerful data source. Currently the healthcare system is limited by some major blind spots: 90% of clinical drug development fails, and we fail to collect high-quality, large-scale data on early-stage disease. PONS is solving this problem by converting any mobile ultrasound with AI into a powerful high-quality data source. PONS takes point-of-care ultrasound beyond imaging and turns it into a data engine. This ensures that capturing of data on healthy samples, as well as those in early- and later-stage disease can be captured and utilized. Imagine pharmacies and retail stores becoming mini-imaging hubs. Using PONS’s AI-powered pods, rich data can be gathered that fuels drug development, personalized medicine and accelerates the timeline for life-saving treatments.

Get In Touch with PONS

Please tell us a little bit about yourself and why you'd like to get connected. PONS + SOSV will follow up with you via email.


No Offer, Solicitation, Advice, or Recommendation

Except to the extent expressly set forth in materials as may be provided through a password protected area on the SOSV website (the "Materials"), or as otherwise expressly specified by SOSV in writing, nothing on the SOSV website or on any platform or other communications medium owned, operated or otherwise by or on behalf of SOSV, is intended to constitute (i) an offer, or solicitation of an offer, to purchase or sell any security, other asset or service, (ii) investment advice or an offer to provide such advice, or (iii) a basis for making any investment decision. Except as expressly stated by SOSV in writing, neither the SOSV website or any platform or other communications medium owned, operated or otherwise by or on behalf of SOSV, nor any of the Materials make any effort to present a comprehensive or balanced description of SOSV or its investment activities. Please note the SOSV Communication Policy available here.